Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries-Reference-Cited by-同舟云学术

Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries

Published:2017-08-21 Issue:8 Volume:12 Page:e0183235
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Hartmann Bettina^ORCID,Lanzinger Stefanie,Bramlage Peter,Groß Felix,Danne Thomas,Wagner Siegfried,Krakow Dietmar,Zimmermann Artur,Malcharzik Christian,Holl Reinhard W.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference62 articles.

1. Lean versus obese diabetes mellitus patients in the United States minority population;NJ Coleman;J Diabetes Complications,2014

2. Body-mass index and mortality among adults with incident type 2 diabetes;DK Tobias;N Engl J Med,2014

3. Association of weight status with mortality in adults with incident diabetes;MR Carnethon;JAMA,2012

4. BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes;P Kokkinos;Diabetes Care,2012

5. Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort;B Hartmann;Acta Diabetol,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. All-cause Mortality and Incidence of Cardiovascular Diseases in Lean Patients With Newly Diagnosed Type 2 Diabetes;The Journal of Clinical Endocrinology & Metabolism;2024-07-26

2. Socioeconomic gradient of lean diabetes in India: Evidence from National Family Health Survey, 2019–21;PLOS Global Public Health;2024-05-30

3. Interactions between physical activity and psychological factors in the association with the risk of lean type 2 diabetes mellitus;Diabetes and Vascular Disease Research;2024-05

4. Trajectories of fasting glucose and glycated haemoglobin in obese and non‐obese incident diabetes: Results from two large cohort studies;Diabetes, Obesity and Metabolism;2023-06-19

5. Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm;Diabetologie und Stoffwechsel;2023-06-06